Literature DB >> 12146953

Four-state equilibrium unfolding of an scFv antibody fragment.

Idolka Pedroso1, María P Irún, Claudia Machicado, Javier Sancho.   

Abstract

The conformational stability of a single-chain Fv antibody fragment against a hepatitis B surface antigen (anti-HBsAg scFv) has been studied by urea and temperature denaturation followed by fluorescence and circular dichroism. At neutral pH and low protein concentration, it is a well-folded monomer, and its urea and thermal denaturations are reversible. The noncoincidence of the fluorescence and circular dichroism transitions indicates the accumulation in the urea denaturation of an intermediate (I(1)) not previously described in scFv molecules. In addition, at higher urea concentrations, a red-shift in the fluorescence emission maximum reveals an additional intermediate (I(2)), already reported in the denaturation of other scFvs. The urea equilibrium unfolding of the anti-HBsAg scFv is thus four-state. A similar four-state behavior is observed in the thermal unfolding although the intermediates involved are not identical to those found in the urea denaturation. Global analysis of the thermal unfolding data suggests that the first intermediate displays substantial secondary structure and some well-defined tertiary interactions while the second one lacks well-defined tertiary interactions but is compact and unfolds at higher temperature in a noncooperative fashion. Global analysis of the urea unfolding data (together with the modeled structure of the scFv) provides insights into the conformation of the chemical denaturation intermediates and allows calculation of the N-I(1), I(1)-I(2), and I(2)-D free energy differences. Interestingly, although the N-D free energy difference is very large, the N-I(1) one, representing the "relevant" conformational stability of the scFv, is small.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12146953     DOI: 10.1021/bi025742e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

2.  Protposer: The web server that readily proposes protein stabilizing mutations with high PPV.

Authors:  Helena García-Cebollada; Alfonso López; Javier Sancho
Journal:  Comput Struct Biotechnol J       Date:  2022-05-10       Impact factor: 6.155

3.  Buffer-dependent fragmentation of a humanized full-length monoclonal antibody.

Authors:  Branden A Salinas; Hasige A Sathish; Ambarish U Shah; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

4.  The conformational stability and biophysical properties of the eukaryotic thioredoxins of Pisum sativum are not family-conserved.

Authors:  David Aguado-Llera; Ana Isabel Martínez-Gómez; Jesús Prieto; Marco Marenchino; José Angel Traverso; Javier Gómez; Ana Chueca; José L Neira
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

5.  Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity.

Authors:  Jian-Xin Zhao; Lian Yang; Zhen-Nan Gu; Hai-Qin Chen; Feng-Wei Tian; Yong-Quan Chen; Hao Zhang; Wei Chen
Journal:  Int J Mol Sci       Date:  2010-12-23       Impact factor: 5.923

6.  Rational stabilization of complex proteins: a divide and combine approach.

Authors:  Emilio Lamazares; Isabel Clemente; Marta Bueno; Adrián Velázquez-Campoy; Javier Sancho
Journal:  Sci Rep       Date:  2015-03-16       Impact factor: 4.379

7.  Defining the nature of thermal intermediate in 3 state folding proteins: apoflavodoxin, a study case.

Authors:  Rebeca García-Fandiño; Pau Bernadó; Sara Ayuso-Tejedor; Javier Sancho; Modesto Orozco
Journal:  PLoS Comput Biol       Date:  2012-08-23       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.